Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ALLO-ASC-DFU for Deep Second-Degree Burns
NCT02394873Phase 1Completed
- Sponsor
- Anterogen Co., Ltd.
- Start
- Mar 2015
- Primary completion
- Aug 2015
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allo-asc in deep second-degree burn, sponsored by Anterogen Co., Ltd. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 4 weeks. Started Mar 2015; status: completed.
02
Drugs
allo-asc
03
Conditions
deep second-degree burn
Beyond the preview
Go deeper on NCT02394873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02394873.